Revenue ($USD) : $27,400,000,000
R&D spend : $2,488,000,000.00
Employees : not available
Fiscal year end : 01/03/23
CEO : Joaquin Duato, CEO; Ashley McEvoy, EVP and J&J MedTech worldwide chair

Johnson & Johnson will have a new focus on medtech and pharmaceuticals now that it's spinning off its consumer business as a new public company called Kenvue.

In December, J&J boosted the profile of J&J MedTech inside the company through its $16.6 billion acquisition of Abiomed and its Impella heart pump portfolio for treating coronary artery disease and heart failure.

Meanwhile, EVP and MedTech worldwide chair Ashley McEvoy joined the ranks of J&J’s top-paid executives and started a two-year term as chair of the trade group AdvaMed.

Biosense Webster, which has a new president, Jasmina Brooks, is another bright spot. It’s launched an atrial fibrillation (AFib) mapping catheter called Optrell with TrueRef technology. Biosense Webster is also moving forward with its investigational Thermocool SmartTouch SF dual energy catheter for treating AFib. The system enables doctors performing an ablation to toggle between two types of energy: pulsed-field and radiofrequency. It appears to be Johnson & Johnson MedTech’s answer to Affera, which competitor Medtronic acquired for $1 billion last year.

As for the DePuy Synthes ortho device business, it has a new major partnership with GE HealthCare in the spine surgery space.

On the flip side, the company remains mostly quiet about its Ottava surgical robotics system, with surgical robotics among the areas where J&J MedTech cut jobs earlier this year. –CN